TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Subject-blind, Investigator-blind, Placebo-controlled, Single-dose, Dose-escalating Study Evaluating the Safety, Pharmacokinetics, and Pharmacodynamics of UCB4940 in Patients With Mild to Moderate Psoriasis
Brief Summary: To evaluate the safety of UCB4940 administered by iv infusion of a single ascending dose in subjects with mild to moderate plaque psoriasis.


Options:
A: Arm Label: UCB4940 8 mg; Type: EXPERIMENTAL; Interventions: Drug: UCB4940 | Arm Label: UCB4940 40 mg; Type: EXPERIMENTAL; Interventions: Drug: UCB4940 | Arm Label: UCB4940 160 mg; Type: EXPERIMENTAL; Interventions: Drug: UCB4940 | Arm Label: UCB4940 480 mg; Type: EXPERIMENTAL; Interventions: Drug: UCB4940 | Arm Label: UCB4940 640 mg; Type: EXPERIMENTAL; Interventions: Drug: UCB4940 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DRUG; Name: UCB4940; Assigned to Arm(s): UCB4940 160 mg, UCB4940 40 mg, UCB4940 480 mg, UCB4940 640 mg, UCB4940 8 mg | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: Therapeutic drug monitoring; Type: EXPERIMENTAL; Interventions: Other: Therapeutic drug monitoring | Arm Label: Standard care; Type: ACTIVE_COMPARATOR; Interventions: Other: Standard care | Intervention Type: OTHER; Name: Therapeutic drug monitoring; Assigned to Arm(s): Therapeutic drug monitoring | Intervention Type: OTHER; Name: Standard care; Assigned to Arm(s): Standard care
C: Arm Label: adalimumab + placebo; Type: ACTIVE_COMPARATOR; Interventions: Biological: adalimumab, Drug: placebo (vehicle ointment) | Arm Label: adalimumab + calcipotriol/betamethasone; Type: ACTIVE_COMPARATOR; Interventions: Biological: adalimumab, Drug: Calcipotriol/Betamethasone Ointment | Intervention Type: BIOLOGICAL; Name: adalimumab; Assigned to Arm(s): adalimumab + calcipotriol/betamethasone, adalimumab + placebo | Intervention Type: DRUG; Name: Calcipotriol/Betamethasone Ointment; Assigned to Arm(s): adalimumab + calcipotriol/betamethasone | Intervention Type: DRUG; Name: placebo (vehicle ointment); Assigned to Arm(s): adalimumab + placebo
D: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: 50 mg etanercept; Type: ACTIVE_COMPARATOR; Interventions: Drug: 50 mg etanercept | Arm Label: 80 mg ixekizumab Dosing Regimen 2; Type: EXPERIMENTAL; Interventions: Drug: 80 mg ixekizumab | Arm Label: 80 mg ixekizumab Dosing Regimen 1; Type: EXPERIMENTAL; Interventions: Drug: 80 mg ixekizumab | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: 50 mg etanercept; Assigned to Arm(s): 50 mg etanercept | Intervention Type: DRUG; Name: 80 mg ixekizumab; Assigned to Arm(s): 80 mg ixekizumab Dosing Regimen 1, 80 mg ixekizumab Dosing Regimen 2

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Subject-blind, Investigator-blind, Placebo-controlled, Single-dose, Dose-escalating Study Evaluating the Safety, Pharmacokinetics, and Pharmacodynamics of UCB4940 in Patients With Mild to Moderate Psoriasis
Brief Summary: To evaluate the safety of UCB4940 administered by iv infusion of a single ascending dose in subjects with mild to moderate plaque psoriasis.


Options:
A: Arm Label: CNTO 1275 45 mg; Type: EXPERIMENTAL; Interventions: Drug: CNTO 1275 45 mg | Arm Label: CNTO 1275 90 mg; Type: EXPERIMENTAL; Interventions: Drug: CNTO 1275 90 mg | Arm Label: Etanercept 50 mg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Etanercept 50 mg | Intervention Type: DRUG; Name: CNTO 1275 45 mg; Assigned to Arm(s): CNTO 1275 45 mg | Intervention Type: DRUG; Name: CNTO 1275 90 mg; Assigned to Arm(s): CNTO 1275 90 mg | Intervention Type: DRUG; Name: Etanercept 50 mg; Assigned to Arm(s): Etanercept 50 mg
B: Intervention Type: DRUG; Name: adalimumab; Assigned to Arm(s): N/A
C: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: 50 mg etanercept; Type: ACTIVE_COMPARATOR; Interventions: Drug: 50 mg etanercept | Arm Label: 80 mg ixekizumab Dosing Regimen 2; Type: EXPERIMENTAL; Interventions: Drug: 80 mg ixekizumab | Arm Label: 80 mg ixekizumab Dosing Regimen 1; Type: EXPERIMENTAL; Interventions: Drug: 80 mg ixekizumab | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: 50 mg etanercept; Assigned to Arm(s): 50 mg etanercept | Intervention Type: DRUG; Name: 80 mg ixekizumab; Assigned to Arm(s): 80 mg ixekizumab Dosing Regimen 1, 80 mg ixekizumab Dosing Regimen 2
D: Arm Label: UCB4940 8 mg; Type: EXPERIMENTAL; Interventions: Drug: UCB4940 | Arm Label: UCB4940 40 mg; Type: EXPERIMENTAL; Interventions: Drug: UCB4940 | Arm Label: UCB4940 160 mg; Type: EXPERIMENTAL; Interventions: Drug: UCB4940 | Arm Label: UCB4940 480 mg; Type: EXPERIMENTAL; Interventions: Drug: UCB4940 | Arm Label: UCB4940 640 mg; Type: EXPERIMENTAL; Interventions: Drug: UCB4940 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DRUG; Name: UCB4940; Assigned to Arm(s): UCB4940 160 mg, UCB4940 40 mg, UCB4940 480 mg, UCB4940 640 mg, UCB4940 8 mg | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Subject-blind, Investigator-blind, Placebo-controlled, Single-dose, Dose-escalating Study Evaluating the Safety, Pharmacokinetics, and Pharmacodynamics of UCB4940 in Patients With Mild to Moderate Psoriasis
Brief Summary: To evaluate the safety of UCB4940 administered by iv infusion of a single ascending dose in subjects with mild to moderate plaque psoriasis.


Options:
A: Arm Label: CP 690,550 5 mg BID+Placebo BIW; Type: EXPERIMENTAL; Interventions: Drug: CP 690,550 5 mg | Arm Label: CP 690,550 10 mg BID+Placebo BIW; Type: EXPERIMENTAL; Interventions: Drug: CP 690,550 10 mg | Arm Label: Placebo BID+Etanercept 50 mg BIW; Type: ACTIVE_COMPARATOR; Interventions: Biological: Etanercept 50 mg | Arm Label: Placebo BID+Placebo BIW; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DRUG; Name: CP 690,550 5 mg; Assigned to Arm(s): CP 690,550 5 mg BID+Placebo BIW | Intervention Type: DRUG; Name: CP 690,550 10 mg; Assigned to Arm(s): CP 690,550 10 mg BID+Placebo BIW | Intervention Type: BIOLOGICAL; Name: Etanercept 50 mg; Assigned to Arm(s): Placebo BID+Etanercept 50 mg BIW | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo BID+Placebo BIW
B: Arm Label: Secukinumab; Type: EXPERIMENTAL; Interventions: Drug: Secukinumab | Arm Label: Ustekinumab; Type: ACTIVE_COMPARATOR; Interventions: Drug: Ustekinumab | Intervention Type: DRUG; Name: Secukinumab; Assigned to Arm(s): Secukinumab | Intervention Type: DRUG; Name: Ustekinumab; Assigned to Arm(s): Ustekinumab
C: Arm Label: UCB4940 8 mg; Type: EXPERIMENTAL; Interventions: Drug: UCB4940 | Arm Label: UCB4940 40 mg; Type: EXPERIMENTAL; Interventions: Drug: UCB4940 | Arm Label: UCB4940 160 mg; Type: EXPERIMENTAL; Interventions: Drug: UCB4940 | Arm Label: UCB4940 480 mg; Type: EXPERIMENTAL; Interventions: Drug: UCB4940 | Arm Label: UCB4940 640 mg; Type: EXPERIMENTAL; Interventions: Drug: UCB4940 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DRUG; Name: UCB4940; Assigned to Arm(s): UCB4940 160 mg, UCB4940 40 mg, UCB4940 480 mg, UCB4940 640 mg, UCB4940 8 mg | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: Ixekizumab; Type: EXPERIMENTAL; Interventions: Drug: Ixekizumab | Arm Label: Fumaric Acid Esters; Type: ACTIVE_COMPARATOR; Interventions: Drug: Fumaric Acid Esters, Drug: Ixekizumab | Arm Label: Methotrexate; Type: ACTIVE_COMPARATOR; Interventions: Drug: Methotrexate, Drug: Ixekizumab | Intervention Type: DRUG; Name: Fumaric Acid Esters; Assigned to Arm(s): Fumaric Acid Esters | Intervention Type: DRUG; Name: Methotrexate; Assigned to Arm(s): Methotrexate | Intervention Type: DRUG; Name: Ixekizumab; Assigned to Arm(s): Fumaric Acid Esters, Ixekizumab, Methotrexate

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Subject-blind, Investigator-blind, Placebo-controlled, Single-dose, Dose-escalating Study Evaluating the Safety, Pharmacokinetics, and Pharmacodynamics of UCB4940 in Patients With Mild to Moderate Psoriasis
Brief Summary: To evaluate the safety of UCB4940 administered by iv infusion of a single ascending dose in subjects with mild to moderate plaque psoriasis.


Options:
A: Arm Label: Etanercept; Type: EXPERIMENTAL; Interventions: Drug: Etanercept | Intervention Type: DRUG; Name: Etanercept; Assigned to Arm(s): Etanercept
B: Arm Label: LAS41008; Type: EXPERIMENTAL; Interventions: Drug: LAS41008 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: LASW1835; Type: ACTIVE_COMPARATOR; Interventions: Drug: LASW1835 | Intervention Type: DRUG; Name: LAS41008; Assigned to Arm(s): LAS41008 | Intervention Type: DRUG; Name: LASW1835; Assigned to Arm(s): LASW1835 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Investigational drug - Dose 1; Type: EXPERIMENTAL; Interventions: Drug: ACT-128800 | Arm Label: Investigational drug - Dose 2; Type: EXPERIMENTAL; Interventions: Drug: ACT-128800 | Arm Label: Matching placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: ACT-128800; Assigned to Arm(s): Investigational drug - Dose 1, Investigational drug - Dose 2 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Matching placebo
D: Arm Label: UCB4940 8 mg; Type: EXPERIMENTAL; Interventions: Drug: UCB4940 | Arm Label: UCB4940 40 mg; Type: EXPERIMENTAL; Interventions: Drug: UCB4940 | Arm Label: UCB4940 160 mg; Type: EXPERIMENTAL; Interventions: Drug: UCB4940 | Arm Label: UCB4940 480 mg; Type: EXPERIMENTAL; Interventions: Drug: UCB4940 | Arm Label: UCB4940 640 mg; Type: EXPERIMENTAL; Interventions: Drug: UCB4940 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DRUG; Name: UCB4940; Assigned to Arm(s): UCB4940 160 mg, UCB4940 40 mg, UCB4940 480 mg, UCB4940 640 mg, UCB4940 8 mg | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Controlled Trial Evaluating Methods to Use Physical Activity to Improve Outcomes After Acute Coronary Syndrome
Brief Summary: This study will use a randomized, controlled trial to test the effectiveness of a home-based physical activity program using wearable devices and financial incentives. All participants in will establish a baseline step count during the first two weeks and then proceed to a 16-week intervention period and 8-week follow-up period.


Options:
A: Arm Label: Control; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Daily feedback | Arm Label: Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Financial incentive, Behavioral: Daily feedback | Intervention Type: BEHAVIORAL; Name: Financial incentive; Assigned to Arm(s): Intervention | Intervention Type: BEHAVIORAL; Name: Daily feedback; Assigned to Arm(s): Control, Intervention
B: Arm Label: Exercise; Type: EXPERIMENTAL; Interventions: Other: Exercise, Other: Cardiovascular Risk Factors | Arm Label: Exercise afther Microcurrent; Type: EXPERIMENTAL; Interventions: Other: Exercise, Device: Microcurrent, Other: Cardiovascular Risk Factors | Arm Label: Cardiovascular Risk Factors; Type: OTHER; Interventions: Other: Cardiovascular Risk Factors | Intervention Type: OTHER; Name: Exercise; Assigned to Arm(s): Exercise, Exercise afther Microcurrent | Intervention Type: DEVICE; Name: Microcurrent; Assigned to Arm(s): Exercise afther Microcurrent | Intervention Type: OTHER; Name: Cardiovascular Risk Factors; Assigned to Arm(s): Cardiovascular Risk Factors, Exercise, Exercise afther Microcurrent
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Rehabilitation in institution | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Rehabilitation at home, Behavioral: Out-patient rehabilitation at the hospital | Intervention Type: BEHAVIORAL; Name: Rehabilitation in institution; Assigned to Arm(s): 1 | Intervention Type: BEHAVIORAL; Name: Rehabilitation at home; Assigned to Arm(s): 2 | Intervention Type: BEHAVIORAL; Name: Out-patient rehabilitation at the hospital; Assigned to Arm(s): 2
D: Arm Label: Experimental group; Type: EXPERIMENTAL; Interventions: Other: Exercise-based cardiac rehabilitation program | Arm Label: Control group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Exercise-based cardiac rehabilitation program; Assigned to Arm(s): Experimental group

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Controlled Trial Evaluating Methods to Use Physical Activity to Improve Outcomes After Acute Coronary Syndrome
Brief Summary: This study will use a randomized, controlled trial to test the effectiveness of a home-based physical activity program using wearable devices and financial incentives. All participants in will establish a baseline step count during the first two weeks and then proceed to a 16-week intervention period and 8-week follow-up period.


Options:
A: Arm Label: Aerobic Exercise Program; Type: EXPERIMENTAL; Interventions: Behavioral: Aerobic Exercise Program | Arm Label: Usual Care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Aerobic Exercise Program; Assigned to Arm(s): Aerobic Exercise Program
B: Arm Label: Home-based training; Type: EXPERIMENTAL; Interventions: Behavioral: Home-based training | Arm Label: Centre-based training; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Centre-based training | Intervention Type: BEHAVIORAL; Name: Home-based training; Assigned to Arm(s): Home-based training | Intervention Type: BEHAVIORAL; Name: Centre-based training; Assigned to Arm(s): Centre-based training
C: Arm Label: Control; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Daily feedback | Arm Label: Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Financial incentive, Behavioral: Daily feedback | Intervention Type: BEHAVIORAL; Name: Financial incentive; Assigned to Arm(s): Intervention | Intervention Type: BEHAVIORAL; Name: Daily feedback; Assigned to Arm(s): Control, Intervention
D: Arm Label: Hospital-based; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Shared care Model; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Shared Care model | Intervention Type: BEHAVIORAL; Name: Shared Care model; Assigned to Arm(s): Shared care Model

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effectiveness of a Multi-faceted Intervention to Improve Supportive Care for Family Caregivers of Patients With Lung Cancer
Brief Summary: Family caregivers play a crucial role in cancer patients care, as they are their principal source of support. It is well recommended to provide them with the resources, information and support needed to maintain a good health, and to sustain their caregiving role. Recently, oncology centres have implemented systematic distress screening programs, but the focus has been limited to cancer patients, with little intervention on family caregivers. This study aims to address this gap. It will implement and test the effectiveness of a simple intervention integrating primary care and oncology care that transfers into practice the main recommendations of governmental authorities and experts to globally improve supportive care. The intervention includes systematic distress screening and problems assessment of family caregivers at diagnosis, and every two months, privileged contact with a nurse away from the patient to address caregivers distress and identified problems, and for caregivers experiencing high level of distress, liaison by the study nurse with their family physician to transfer information on their identified problems and level of distress and to facilitate shared follow-up. This intervention has been pilot-tested with family caregivers, health care providers and decision makers involved in lung cancer care, as well as with community-based family physicians, to ensure its feasibility and acceptability. This study findings may clearly improve patient and caregiver experience of cancer care, and reduce the burden of disease.


Options:
A: Arm Label: Psychological Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Psychological intervention | Arm Label: Usual care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Psychological intervention; Assigned to Arm(s): Psychological Intervention
B: Arm Label: Experimental: supportive care; Type: EXPERIMENTAL; Interventions: Other: Supportive care | Arm Label: Control: usual care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Supportive care; Assigned to Arm(s): Experimental: supportive care
C: Arm Label: Psycho-educational support group therapy; Type: EXPERIMENTAL; Interventions: Behavioral: Psycho-educational support group therapy | Intervention Type: BEHAVIORAL; Name: Psycho-educational support group therapy; Assigned to Arm(s): Psycho-educational support group therapy
D: Arm Label: Nueva Vida Intervention; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Nueva Vida Intervention | Arm Label: Usual Care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Nueva Vida Intervention; Assigned to Arm(s): Nueva Vida Intervention

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Is There Any Analgesic Benefit From Preoperative vs. Postoperative Etoricoxib Administration in Total Knee Arthroplasty?
Brief Summary: Evaluation of the efficacy of preemptive versus postoperative administration of etoricoxib in total knee arthroplasty (TKA).


Options:
A: Arm Label: Treatment A:; Type: ACTIVE_COMPARATOR; Interventions: Drug: Paracetamol (1g x 4), Drug: Ibuprofen (400 mg x 4) | Arm Label: Treatment B:; Type: ACTIVE_COMPARATOR; Interventions: Drug: Paracetamol (1g x 4), Drug: Placebo (x4) | Arm Label: Treatment C:; Type: ACTIVE_COMPARATOR; Interventions: Drug: Ibuprofen (400 mg x 4), Drug: Placebo (x4) | Arm Label: Treatment D:; Type: ACTIVE_COMPARATOR; Interventions: Drug: Paracetamol (0,5 g x 4), Drug: Ibuprofen (200 mg x 4) | Intervention Type: DRUG; Name: Paracetamol (1g x 4); Assigned to Arm(s): Treatment A:, Treatment B: | Intervention Type: DRUG; Name: Ibuprofen (400 mg x 4); Assigned to Arm(s): Treatment A:, Treatment C: | Intervention Type: DRUG; Name: Paracetamol (0,5 g x 4); Assigned to Arm(s): Treatment D: | Intervention Type: DRUG; Name: Ibuprofen (200 mg x 4); Assigned to Arm(s): Treatment D: | Intervention Type: DRUG; Name: Placebo (x4); Assigned to Arm(s): Treatment B:, Treatment C:
B: Arm Label: Group ETORICOXIB PREOP; Type: EXPERIMENTAL; Interventions: Drug: Etoricoxib, Drug: Placebo | Arm Label: Group ETORICOXIB POSTOP; Type: EXPERIMENTAL; Interventions: Drug: Etoricoxib, Drug: Placebo | Arm Label: Group PLACEBO; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Etoricoxib; Assigned to Arm(s): Group ETORICOXIB POSTOP, Group ETORICOXIB PREOP | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Group ETORICOXIB POSTOP, Group ETORICOXIB PREOP, Group PLACEBO
C: Arm Label: Dexketoprofen trometamol; Type: EXPERIMENTAL; Interventions: Drug: Dexketoprofen trometamol | Arm Label: Preoperative control; Type: PLACEBO_COMPARATOR; Interventions: Drug: Preoperative control | Intervention Type: DRUG; Name: Dexketoprofen trometamol; Assigned to Arm(s): Dexketoprofen trometamol | Intervention Type: DRUG; Name: Preoperative control; Assigned to Arm(s): Preoperative control
D: Arm Label: Preemptive; Type: ACTIVE_COMPARATOR; Interventions: Drug: Etoricoxibe | Arm Label: Postoperative; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Etoricoxibe; Assigned to Arm(s): Preemptive | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Postoperative

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Phase 2 Randomized Control Trial of Arginine Therapy for Pediatric Sickle Cell Disease Pain
Brief Summary: The aim of this study is to determine whether giving extra arginine, a simple amino acid, to patients with sickle cell disease seeking treatment for a pain crisis (vaso-occlusive painful events (VOE) will decrease pain scores, decrease the need for pain medications or decrease length of hospital stay or emergency department visit. Funding Source - FDA OOPD.


Options:
A: Arm Label: Low Dose; Type: ACTIVE_COMPARATOR; Interventions: Drug: Arginine | Arm Label: High Dose; Type: ACTIVE_COMPARATOR; Interventions: Drug: Arginine | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Arginine; Assigned to Arm(s): High Dose, Low Dose | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: L-Arginine; Type: EXPERIMENTAL; Interventions: Drug: L-arginine | Arm Label: Loading Dose and L-Arginine; Type: EXPERIMENTAL; Interventions: Drug: L-arginine, Drug: L-arginine Loading Dose | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DRUG; Name: L-arginine; Assigned to Arm(s): L-Arginine, Loading Dose and L-Arginine | Intervention Type: DRUG; Name: L-arginine Loading Dose; Assigned to Arm(s): Loading Dose and L-Arginine | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: LOVAZA; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Omega-3 Fatty Acids: Eicosapentaenoic Acid (EPA) and Docosahexaenoic Acid (DHA) | Arm Label: Placebo capsule; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo Capsules | Intervention Type: DIETARY_SUPPLEMENT; Name: Omega-3 Fatty Acids: Eicosapentaenoic Acid (EPA) and Docosahexaenoic Acid (DHA); Assigned to Arm(s): LOVAZA | Intervention Type: OTHER; Name: Placebo Capsules; Assigned to Arm(s): Placebo capsule
D: Arm Label: L-glutamine; Type: EXPERIMENTAL; Interventions: Drug: L-glutamine | Arm Label: 100% maltodextrin; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: L-glutamine; Assigned to Arm(s): L-glutamine | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 100% maltodextrin

Answer: B